SCHEMBL6078078

SCHEMBL6078078

NC(=O)[C@@H]1CCC[C@@H]1NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
MAPK1 P28482 1/20 0.51
THRB P10828 1/20 0.51
LMNA P02545 5/20 0.50
CRHBP P24387 3/20 0.50
CRHR2 Q13324 3/20 0.50
GAA P10253 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MCOLN3 Q8TDD5 1/20 0.50
HSP90AA1 P07900 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
F10 P00742 1/20 0.47
KDM4E B2RXH2 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MMP2 P08253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6078074 1.00 ALDH1A1 (0.51) ALDH1A1MAPK1THRBLMNACRHBP
SCHEMBL6078081 1.00 ALDH1A1 (0.51) ALDH1A1MAPK1THRBLMNACRHBP
SCHEMBL6265626 0.97 MAPK1 (0.54) ALDH1A1MAPK1THRBLMNACRHBP
SCHEMBL6078735 0.97 MAPK1 (0.54) ALDH1A1MAPK1THRBLMNACRHBP
SCHEMBL6077223 0.97 MAPK1 (0.54) ALDH1A1MAPK1THRBLMNACRHBP
SCHEMBL6078711 0.97 MAPK1 (0.54) ALDH1A1MAPK1THRBLMNACRHBP
SCHEMBL6078229 0.97 MAPK1 (0.54) ALDH1A1MAPK1THRBLMNACRHBP
SCHEMBL6078980 0.97 MAPK1 (0.54) ALDH1A1MAPK1THRBLMNACRHBP
SCHEMBL6078669 0.96 MAPK1 (0.53) ALDH1A1MAPK1THRBLMNACRHBP
SCHEMBL6078665 0.96 MAPK1 (0.53) ALDH1A1MAPK1THRBLMNACRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084178-B2 Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-01 US disclosed
WO-2005054180-A1 ANTIAMYLOID PHENYLSULFONAMIDES: N-CYCLOALKYLCARBOXAMIDES DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2005-06-16 WO disclosed
US-20050113442-A1 Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives BRISTOL-MYERS SQUIBB COMPANY 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113442-A1 Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives APP, PSEN1, PSEN2 ALDH1A1 3997/4885MAPK1 2739/4885THRB 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.